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ABSTRACT
Because survival of recipients of allogeneic hematopoietic stem cell transplantation (HSCT) has improved,
long-term complications become more important. We studied the incidence and risk factors of chronic
kidney disease in these patients and evaluated associated posttransplant complications and mortality. We
performed a retrospective cohort study of 266 adults who received myeloablative allogeneic HSCT and
who survived for >6 months in an 11-year period at a Dutch university medical center. Primary outcome
was the incidence of chronic kidney disease defined as a glomerular filtration rate (GFR) of <60 mL/min/
1.73 m2. Chronic kidney disease developed in 61 (23%) of 266 patients, with a cumulative incidence rate
of 27% at 10 years. Severe kidney disease (GFR of <30 mL/min/1.73 m2) developed in 3% of patients. Only
6 patients developed the thrombotic microangiopathic syndrome SCT nephropathy, and 2 of them needed
dialysis. Pretransplant risk factors for chronic kidney disease were lower GFR at day 0 (P < .0001, odds
ratio [OR] 0.95 95% confidence interval [CI] 0.93-0.97), female gender, and higher age (P  .001 and P <
.0001, respectively). The occurrence of hypertension after transplantation was associated with chronic
kidney disease (P < .0001, OR 0.34 95% CI 0.18-0.62). Mortality was 39% after a mean follow-up of 5.1
years. There was no significant difference in survival between patients with and without chronic kidney
disease. Chronic kidney disease is a common late complication of myeloablative allogeneic HSCT. Because
of the natural decline in renal function with time there is a risk of developing end-stage renal disease in
the future. SCT nephropathy seems to be a specific cause of chronic kidney disease that is typically
associated with severe kidney disease.
© 2007 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
Chronic kidney disease in the general population
s considered to be a public health problem [1]. There
s a rising incidence and prevalence of kidney failure
2]. Risk factors include older age, hypertension, dia-
etes, cardiovascular disease, and a family history of
he disease [1]. Detection, evaluation, and manage-
ent of chronic kidney disease according to the Na-
ional Kidney Foundation Kidney Disease Outcomes
uality Initiative (K/DOQI) guidelines are essential
n order to slow progression of chronic kidney disease
o kidney failure [2]. More patient groups are now [eing identiﬁed for whom the guidelines are recom-
ended because of an increased risk of developing
hronic kidney disease, for example, recipients of
eart and lung transplantations [3]. It is not well es-
ablished whether chronic kidney disease is a frequent
omplication of nonsolid organ transplantation [4].
llogeneic hematopoietic stem cell transplantation
HSCT) after intensive chemotherapy and total-body
rradiation (TBI; myeloablative conditioning) is a
idely accepted approach in the treatment of several
ematologic malignancies. Annually approximately
0,000 adults receive an allogeneic HSCT worldwide
5]. Because many recipients of SCT now have long-
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S. Kersting et al.1170erm survival, late complications, like chronic kidney
isease, become more important [6]. One of the causes
f chronic kidney disease after allogeneic SCT is a
icroangiopathic syndrome called SCT nephropathy.
his syndrome typically occurs 8 to12 months follow-
ng SCT with the triad hypertension, progressive re-
al failure, and disproportionate severe anemia [7].
owever, most cases of chronic kidney disease after
CT are not accompanied by signs of microangiopa-
hy [8]. Risk factors described for chronic kidney dis-
ase after SCT are TBI [9], TBI dose and graft-
ersus-host disease (GVHD) [10], the absence of renal
hielding during TBI [11], angiotensin-converting en-
yme gene polymorphism [12], age, and previous ﬂu-
arabine administration [8]. Up to now, most of stud-
es analyzing this form of chronic kidney disease have
ean follow-up of 3 years [8-11], or few patients
ith longer follow-up [12], and, therefore, incidence
nd causes are not well established [4].
The aim of this study was to investigate incidence
nd pretransplant risk factors of chronic kidney dis-
ase in recipients of myeloablative allogeneic SCT
ith a long follow-up, and to determine posttrans-
lant complications and mortality associated with
hronic kidney disease.
ATERIALS AND METHODS
tudy Design
Between January 1, 1993, and January 1, 2004,
yeloablative allogeneic HSCT was performed in 363
dult patients aged 17-57 years at the department of
ematology of the University Medical Centre Utrecht.
ecause the primary outcome of this study was
hronic kidney disease we excluded patients with a
urvival of6 months (n 92) and patients with renal
ysfunction at baseline (n  5) (a glomerular ﬁltration
ate [GFR] of 60 mL/min/1.73m22 or creatinine
110 mol/L). Of these 266 patients data were col-
ected retrospectively using a data base and comput-
rized patient records through February 1, 2006. Pa-
ients were treated according to clinical protocols
pproved by the local investigation review board and
ave informed consent.
tudy Population
All patients received a myeloablative conditioning
egimen that consisted of cyclophosphamide (60 mg/
g/day for 2 days), followed by TBI (600 cGy/day for
days) with partial shielding of the lungs (total lung
ose 850 cGy) and partial shielding of the kidneys
500 cGy/day for 2 days). After the second TBI frac-
ion on day 0, the graft was infused. In recipients of
istocompatibility leukocyte antigen (HLA)-matched
nrelated donor or a single HLA-antigen mismatched
amily donor, antithymocyte globulin (Rabbit ATG) rThymoglobulin™, Sangstat, Amstelveen, The Neth-
rlands) was given before cyclophosphamide was in-
used. The graft was partial T cell depleted as de-
cribed earlier [13]. All patients received GVHD
rophylaxis with cyclosporine, which was started on
ay 2 in a dose of 3 mg/kg/day by continuous infu-
ion for 3-4 weeks, thereafter given orally for 4-6
eeks in a dose that gave comparable trough levels.
ose adjustments were made to keep cyclosporine
rough levels between 200 and 450 ng/mL. When no
ctive GVHD was present, cyclosporine was discon-
inued within 3 months after transplantation. GVHD
as diagnosed according to the Seattle criteria [14].
ctive graft-versus-host disease (aGVHD) grade I was
reated with topical corticosteroids. aGVHD grade II
r higher was treated with high-dose systemic corti-
osteroids. Limited cGVHD was not treated and ex-
ensive cGVHD was treated with systemic corticoste-
oids.
Infection prophylaxis consisted of ciproﬂoxacin,
uconazole, and amphotericin B given orally until
ranulocyte counts exceeded 500 cell/L. Cephalotin
as given intravenously from day 3 until day 13.
otrimoxazol 480 mg twice daily and valacyclovir 500
g twice daily were given orally from day 1 until 12
onths after transplantation or longer in case of active
VHD.
ata Collection
The following data on pretransplant risk factors
ere collected: history of hypertension, previous au-
ologous transplantation, sex, age, type of transplant,
ismatched transplant, underlying disease, presence
f high-risk malignancy, and estimated GFR on day 0.
or each patient serum creatinine was collected at day
, 6 months after SCT, 12 months after SCT, and
hereafter annually.
The following complications were recorded: (1)
cute renal failure, (2) aGVHD, cGVHD and the
uration of cyclosporine use in patients with aGVHD,
GVHD, (3) thrombotic thrombocytopenic purpura
TTP), (4) sinusoidal occlusion syndrome, (5) cyto-
egalovirus (CMV) reactivation, (6) hypertension,
nd (7) the occurrence of SCT nephropathy.
Mortality data were collected.
efinitions
Patients with acute leukemia in ﬁrst complete re-
ission (CR1), chronic myelogenous leukemia (CML)
n ﬁrst chronic phase, and untreated severe aplastic
nemia were considered low risk; all other hemato-
ogic diseases were considered high risk.
Acute renal failure was deﬁned as doubling of
aseline serum creatinine within 3 months after trans-
lantation. TTP was deﬁned as simultaneous occur-
ence of thrombocytopenia and hemolytic anemia
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Chronic Kidney Disease after SCT 1171ith red cell fragmentation, raised lactate dehydroge-
ase, raised bilirubin, and decreased haptoglobin level,
f this occurred within 3 months after transplantation.
inusoidal occlusion syndrome was deﬁned as hyper-
ilirubinemia, right upper quadrant pain, and weight
ain occurring within 20 days posttransplantation.
ypertension was deﬁned as a systolic pressure of 140
mHg or higher or a diastolic blood pressure of 90
mHg or higher or receiving medication for treat-
ent of hypertension.
Chronic kidney disease was deﬁned according to
he K/DOQI deﬁnition of kidney disease [2]. Stage 3
hronic kidney disease was an estimated GFR 60
L/min/1.73 m2, stage 4 chronic kidney disease was a
FR 30 mL/min/1.73 m2, and stage 5 chronic kid-
ey disease a GFR 15 mL/min/1.73 m2 or need for
ialysis [2,8]. Only if low GFR developed after at least
months after SCT and persisted until death or last
ollow-up was the patient deﬁned as having chronic
idney disease. Estimated GFR was calculated using
he Modiﬁcation of Diet in Renal Disease (MDRD)
tudy equation, deﬁned as GFR  186.3  (serum
reatinine)1.154  age0.203  (0.742 for women)
15]. SCT nephropathy was deﬁned as the triad of
ypertension, hemoglobin of 6.0 mmol/L, and rise
n serum creatinine to 250 mol/L, with no appar-
nt cause occurring 3 months after transplantation.
tatistical Analysis
Continuous variables are displayed as mean, with
anges in parentheses. For dichotomous variables the
requency of occurrence is given along with the cor-
esponding percentage. Cumulative incidence rates
ere made for chronic kidney disease.
Differences between groups were assessed with
he chi-square test or Fisher’s exact test (where appro-
riate). A 2-sided Student’s t-test was used for contin-
ous variables.
The relative contributions of continuous and di-
hotomous variables on the outcome chronic kidney
isease were examined using stepwise multiple logistic
egressions. Survival was analyzed by the Kaplan-
eier method. All P-values were 2-sided, and a value
f .05 was considered statistically signiﬁcant. All
nalysis was performed using SPSS version 12.0 (SPSS
nc, Chicago, IL).
Competing risk data were used to make a cumu-
ative incidence for chronic kidney disease, with out-
ome being chronic kidney disease, competing risk
eing death without chronic kidney disease, and time
ariable being time to chronic kidney disease, death,
r last follow-up, whichever was ﬁrst. This analysis
as performed using an R-library for multistate mod-
ls and SPSS version 14.0 [16]. wESULTS
Table 1 shows the pretransplant risk factors of the
66 recipients of myeloablative allogeneic SCT. The
ean follow-up time was 5.1 years (range 0.5-13.1
ears). The mean age at day 0 was 38.3 years (range
7-56 years). Chronic kidney disease developed in 61
f 266 patients (23%) after a mean of 2.6 years (range
.5-12 years). Eight of these patients had severe
hronic kidney disease stage 4 and 5, with a GFR 30
L/min/1.73 m2 after a mean of 3.3 years (range
.7-5.4 years) in 6 of them and need for dialysis after
mean of 6.3 years (2.8 and 9.8 years, respectively) in
of them. The cumulative incidence rates for chronic
idney disease were 20% at 5 years and 27% at 10
ears (Figure 1).
The renal function slowly deteriorated in time
Figure 2).
Renal-vascular complications that developed were
s follows: Acute renal failure in 118 patients (44%),
TP in 4 patients (1.5%), hypertension in 46 patients
17%), and SCT nephropathy in 6 patients (2%) (Ta-
le 2). SCT nephropathy was the cause of stage 4
hronic kidney disease in 2 of 6 patients (33%) and the
nly cause of need for dialysis.
Univariate analysis of pretransplant risk factors
evealed that patients who developed chronic kidney
isease were more often women (P .001), were older
P  .0001), had lower GFR (P  .0001), and higher
erum creatinine (P  .026) (Table 1). In multivariate
nalysis only lower estimated GFR (P  .0001, odds
atio [OR] 0.952, 95% conﬁdence interval [CI] 0.933-
.972) was a pretransplant risk factor for chronic kid-
ey disease. Diagnosis, type of transplant, mismatched
ransplant, presence of high-risk malignancy, history
f hypertension, and previous autologous transplanta-
ion did not differ statistically between the groups
ith or without chronic kidney disease.
In univariate and multivariate analysis of post-
ransplant complications only the occurrence of hy-
ertension after transplantation was associated with
hronic kidney disease (P  .0001 and P  .0001, OR
.337, 95% CI 0.184-0.617). Acute renal failure, TTP,
inusoidal occlusion syndrome, aGVHD, cGVHD,
MV reactivation, and longer cyclosporine use did
ot differ statistically between the groups with or
ithout chronic kidney disease.
At day 0, 233 patients (88%) had a GFR 90
L/min/1.73 m2, and 45 of them (19.3%) developed
hronic kidney disease, 33 patients had a GFR be-
ween 61 and 89 mL/min/1.73 m2, and 16 of them
51.5%) developed chronic kidney disease.
Of the patients who developed hypertension after
CT, there was no signiﬁcant difference in the use of
ntihypertensive medication between the patients
ith or without chronic kidney disease.
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S. Kersting et al.1172Mean hemoglobin was signiﬁcantly lower in pa-
ients with chronic kidney disease compared to pa-
ients without chronic kidney disease (P  .004).
Mean follow-up of surviving patients was 7.0 years
range 1.7-13.1 years). Death occurred in 107 patients
able 1. Pretransplant Risk Factors of Patients with and without Chro
Patients with CK
umber of patients 61 (23%)
ex
Male 25 (41%)
Female 36 (59%)
ge (years) mean (range) 43.2 (18-55)
<40 years 19 (31%)
>40 years 42 (69%)
istory
No history 53 (85%)
Hypertension 7 (12%)
Autologous transplantation 2 (3%)
ransplant
Related donor 49 (80%)
Matched unrelated donor 12 (20%)
ismatch
Yes 4 (7%)
No 57 (93%)
isease
AML 13 (21%)
ALL 6 (10%)
CML 15 (25%)
SAA 1 (2%)
MM 12 (20%)
Other 14 (23%)
igh risk
Yes 39 (64%)
No 23 (36%)
aseline sCr (mol/L) mean (range) 68.4 (50-104)
aseline GFR(mL/min/1.73m2) mean (range) 102.5 (61-176)
KD indicates chronic kidney disease; AML, acute myelogenous
leukemia; SAA, severe aplastic anemia; MM, multiple myelomaFigure 1. Cumulative incidence of chronic kidney d39%) after a mean of 2.1 years (range 0.5-12.6 years)
ecause of relapse (18%) or treatment related mortal-
ty (TRM, 21%). There was no signiﬁcant difference
n survival between patients with and without chronic
idney disease (P  .98).
ey Disease (CKD)
atients without
CKD
Univariate
P-Value
Multivariate
P-Value OR (95% CI)
205 (77%)
.001 ns
136 (66%)
72 (34%)
36.8 (17-56) <.0001 ns
112 (55%)
93 (45%)
ns ns
175 (85%)
17 (8%)
13 (6%)
ns ns
150 (73%)
55 (27%)
ns ns
20 (10%)
185 (90%)
ns ns
55 (27%)
37 (18%)
46 (22%)
9 (4%)
23 (11%)
35 (17%)
ns ns
118 (58%)
87 (42%)
64.4 (37-108) .026 ns
122.9 (63-206) <.0001 <.0001 0.95 (0.93-0.97)
ia; ALL, acute lymphatic leukemia; CML, chronic myelogenous
erum creatinine; GFR, glomerular ﬁltration rate.nic Kidn
D
P
leukemisease (CKD) and survival (time in months).
De
d
f
a
a
e
o
b
k
j
y
m
o
f
i
s
h
e
a
c
c
d
t
p
d
l
b
c
G
h
e
d
A
f
C
s
a
d
m
v
d
o
r
c
s
m
o
w
t
c
k
c
c
k
d
1
a
o
i
m
b
c
c
n
t
k
functi
Chronic Kidney Disease after SCT 1173ISCUSSION
In this large study with long follow-up after my-
loablative allogeneic HSCT chronic kidney disease
eveloped in 62 of 271 patients (23%) after mean
ollow up of 5.1 years. This is more than twice as high
s seen in a community-based population with a mean
ge of 43, where 9.4% developed chronic kidney dis-
ase after mean follow-up of 18.5 years [17]. In most
f our patients chronic kidney disease was unnoticed
y their doctors. We found that although chronic
idney disease developed in the ﬁrst year in the ma-
ority of patients it even developed in patients after 12
ears of follow-up. The study that used the same
ethods to determine kidney disease had an incidence
f 12% at 2 years [8].
It is known that chronic kidney disease is a risk
actor for cardiovascular disease [18]. Decreased GFR
s associated with complications in almost all organ
ystems. Among the most important complication are
igh blood pressure, anemia, malnutrition, bone dis-
ase, neuropathy, and decreased overall functioning
nd well being [2]. This was shown in our patient
ohort by lower mean hemoglobin in the group with
hronic kidney disease.
The strongest pretransplant risk factor for the
evelopment of chronic kidney disease was lower es-
imated GFR at day 0. Also, in community-based
opulation studies lower GFR was a predictor for the
evelopment of kidney disease [17]. Therefore, it is
ikely that patients with suboptimal kidney function
efore SCT will have more chance of developing
hronic kidney disease after SCT. Patients with a
FR between 61 and 89 mL/min/1.73 m2 before SCT
ad 50% chance of developing chronic kidney dis-
ase in this study.
Other pretransplant risk factors for chronic kidney
Figure 2. Evolution of kidneyisease in univariate analysis were age and female sex. uge as a risk factor for chronic renal failure was also
ound in another study of patients after SCT [8].
ross-sectional community studies showed progres-
ive decline in renal function with aging [19]. Renal
ging is a natural phenomenon with a course that is
ependent on a combination of genetic and environ-
ental factors. Pathophysiologic mechanisms in-
olved are the renin-angiotensin system activity, re-
uced renal klotho gene expression, increased
xidative stress, and genes involved in cellular cycle
egulation [20]. The association of female sex with
hronic kidney disease is not a new ﬁnding. In other
tudies the cut of value of an estimated GFR of 60
L/min per 1.73 m2 for women was lowered because
f a 50% more incidence of chronic kidney disease in
omen with this cut of value using the MDRD equa-
ion [17].
Hypertension after SCT in our cohort was asso-
iated with chronic kidney disease. Hypertension is
nown to be both a cause and a complication of
hronic kidney disease. Hypertension in patients with
hronic kidney disease is associated with faster loss of
idney function and development of cardiovascular
isease [2]. Furthermore, low target blood pressure of
30/80 mmHg delays the onset of kidney failure [21]
nd, therefore, treatment of hypertension to a target
f 130/80 in patients with chronic kidney disease
s recommended [22]. The use of antihypertensive
edication in our cohort did not differ statistically
etween hypertension patients with or without
hronic kidney disease, suggesting that treatment
ould not prevent the development of chronic kid-
ey disease. However, whether the above men-
ioned targets were met is not known.
Acute renal failure was not associated with chronic
idney disease. Major risk factors for acute renal fail-
on of all patients with CKD.re are sinusoidal occlusion syndrome [23], TTP [24],
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S. Kersting et al.1174GVHD [25-27], and nephrotoxic medication like cy-
losporine [28] and amphothericin B [26]. Because
cute renal failure was not associated with chronic
idney disease, it is unlikely that short-term use of
ephrotoxic medication have caused chronic kidney
isease in this cohort. Longer duration of cyclospor-
ne treatment was not associated with chronic kidney
isease.
Stem cell transplantation nephropathy was associ-
ted with severe chronic kidney disease. It was the
ause of stage 4 chronic kidney disease in 33% of
atients and the only cause for end-stage renal failure.
his microangiopathic syndrome characterized by hy-
ertension, progressive renal failure, and dispropor-
ionate severe anemia resembles radiation nephritis
escribed 50 years ago as a complication of radio-
herapy for seminomas [29]. The role of TBI in the
evelopment of SCT nephropathy seems clear from
revious studies [7-12]. Treatment with ACE inhibi-
ors have shown efﬁcacy in prevention and treatment
able 2. Posttransplant Complications, Treatment, and Mortality of Pa
Patients with CK
umber of patients 61 (23%)
RF
Yes 28 (46%)
No 33 (54%)
OS
Yes 1 (2%)
No 60 (98%)
TP
Yes 1 (2%)
No 60 (98%)
MV reactivation
Yes 11 (18%)
No 50 (82%)
cute GVHD
no-grade I 33 (54%)
II-IV 28 (46%)
hronic GVHD
No 34 (56%)
Limited 14 (23%)
Extensive 13 (21%)
ypertension
Yes 22 (36%)
No 35 (57%)
Missing 4 (7%)
CT nephropathy
Yes 5 (8%)
No 56 (92%)
uration of cyclosporine use† mean (range) 15.5 (4-80)
emoglobin (mmol/L) mean (range) 7.37 (5.0-8.9)
ortality
Alive 35 (57%)
Dead 26 (43%)
KD indicates chronic kidney disease; ARF, acute renal failure; S
purpura; CMV, cytomegalovirus; GVHD, graft-versus-host dis
Died before developing chronic renal failure.
Time in weeks.f SCT nephropathy in experimental rat models. sreatment with ACE inhibitors is recommended for
atients with this complication [30].
Survival was not inﬂuenced by chronic kidney dis-
ase in this cohort. The reason for this might be that
ollow-up was still too short for development of late
omplications of chronic kidney disease.
A limitation of our study is that the mechanisms
nderlying chronic kidney disease after SCT are not
lear. Only 6 patients with chronic kidney disease had
he microangiopathic syndrome SCT nephropathy.
hether thrombotic microangiopathy also plays a
ole in the development of chronic kidney disease in
atients without SCT nephropathy is not clear.
Because all patients had the same conditioning reg-
men, and had the same immune suppression and infec-
ion prophylaxis, it was not possible to asses the risk of
hese components for chronic kidney disease. Therefore,
t remains unknown whether chronic kidney disease is
ssociated with TBI or with the total conditioning reg-
men, or whether it is a side effect of standard immune
ith and without Chronic Kidney Disease (CKD)
atients without
CKD
Univariate
P-Value
Multivariate
P-Value OR (95% CI)
205 (77%)
ns ns
90 (44%)
115 (56%)
ns ns
4 (2%)
201 (98%)
ns ns
3 (2%)
202 (99%)
ns ns
31 (15%)
174 (85%)
ns ns
125 (61%)
80 (39%)
ns ns
129 (63%)
44 (22%)
32 (16%)
<.0001 <.0001 0.34 (0.18-0.62)
24 (12%)
165 (81%)
16 (8%)
1 (1%)*
204 (99%)
19.3 (5-220) ns ns
7.74 (5.1-9.7) .004
ns ns
127 (62%)
78 (38%)
usoidal occlusion syndrome; TTP, thrombotic thrombocytopenic
T, stem cell transplantation.tients w
D
P
OS, sin
ease; SCuppression and antibiotics used after SCT.
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Chronic Kidney Disease after SCT 1175In conclusion, chronic kidney disease is a common
ate complication after SCT developing in 23% of
atients, with a cumulative incidence of 27% at 10
ears posttransplantation. Severe kidney disease devel-
ps in 3% of patients. Chronic kidney disease can
evelop between a half year to 12 years or even later.
ecause of the natural decline in renal function with
ime there is a risk of developing end-stage renal
isease in the future. Pretransplant risk factors for
hronic kidney disease are lower GFR at day 0, higher
ge, and female gender. The occurrence of hyperten-
ion after SCT is associated with chronic kidney dis-
ase. SCT nephropathy seems to be a speciﬁc cause
hat is typically associated with severe kidney disease.
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